Keywords: GlaaxoSmithKline, Fourth-quarter and full-year 2010 results, Avastin
GlaxoSmithKline below forecasts, as Avandia costs and demise pummel sales and lead to massive 4th-qtr 2010 loss
Article | 04 February 2011
UK pharma giant GlaxoSmithKline (LSE: GSK) reported fourth-quarter 2010 net loss of £690 million ($1.12 billion) compared with a profit of £1.63 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
